北京丹擎医药科技

Danqing Biotech is a clinical-stage biopharmaceutical company focused on the development of next-generation precision oncology therapies through synthetic lethality. Founded in 2021 and headquartered in Beijing, the company utilizes its proprietary platform to target the DNA damage response (DDR) and other synthetic lethal pathways. Its lead candidate, DQ-001, is a highly selective ATR inhibitor currently in Phase 1 clinical trials for the treatment of advanced solid tumors. The company's pipeline also features several preclinical assets targeting WEE1 and USP1, aimed at addressing unmet medical needs in cancer patients with specific genetic alterations. Danqing Biotech is led by an experienced R&D team and supported by leading life science investors.